Identification of the best cut-off points and clinical signs specific for early recognition of macrophage activation syndrome in active systemic juvenile idiopathic arthritis

類似資料

• Successful treatment with tocilizumab every 4 weeks of a low disease activity group who achieve a drug-free remission in patients with systemic-onset juvenile idiopathic arthritis
  著者:: Kostik, Mikhail M, 等
  出版事項: (2015)
• PReS-FINAL-2154: The early predictors of fatal outcome of macrophage activation syndrome in pediatric rheumatic diseases
  著者:: Kostik, MM, 等
  出版事項: (2013)
• The Use of Tocilizumab in 40 Patients With Polyarticular Juvenile Idiopathic Arthritis: the Results of a Retrospective Study
  著者:: Mikhail M. Kostik, 等
  出版事項: (2017-06-01)
• The Use of Tocilizumab in 40 Patients With Polyarticular Juvenile Idiopathic Arthritis: the Results of a Retrospective Study
  著者:: Mikhail M. Kostik, 等
  出版事項: (2017-06-01)
• ETANERCEPT TREATMENT RESULTS IN CHILDREN WITH NON-SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS: REMISSION, RECRUDESCENCE, AND ADVERSE EVENTS. RETROSPECTIVE COHORT STUDY
  著者:: Mikhail M. Kostik, 等
  出版事項: (2018-05-01)